Cervical cancer is a disease caused by persistent infection of high-risk human papillomavirus (HPV) in female reproductive tract. Among the malignant tumors of female reproductive system in China, the incidence and mortality of cervical cancer rank first, with about 654.38+million new cases and 30,000 deaths each year. HPV 16 and HPV 18 are the most common types of high-risk human papillomavirus in cervical cancer. In China, more than 84.5% cases of cervical squamous cell carcinoma are related to the persistent infection of these two high-risk human papillomaviruses. The first peak of female high-risk human papillomavirus infection in China is 15 to 24 years old, and the second peak is 40 to 44 years old.
At the same time of carrying out the cervical cancer screening project, the incidence of cervical cancer and precancerous lesions will be significantly reduced by inoculating HPV vaccine among the majority of school-age women, thus reducing the disease burden. As a vaccine specially developed to prevent cervical cancer, sirrah contains antigens against HPV 16 and 18. The patented adjuvant system of AS04 can effectively activate the immune system and produce a lasting and effective immune response. At the same time, because of its excellent cross-protection effect on other high-risk human papillomavirus, sirrah's overall protection effect on cervical precancerous lesions (CIN3+) caused by any high-risk human papillomavirus in uninfected population reached 93.2%.
Dr Thomas Brewer, senior vice president and chief medical officer of GlaxoSmithKline's vaccine division, said: "Cervical cancer has become a disease that can be prevented by vaccines. As a vaccine specially developed to prevent cervical cancer, sirrah's application in Chinese mainland to extend the age of the target to 45 was approved, so that more women can be vaccinated, which is undoubtedly exciting and good news. Since sirrah now covers women aged 9 to 45, it has become the most widely used HPV vaccine in China. "
Content source: Netease News